Trials / Completed
CompletedNCT00363311
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men
A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 302 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the effect of dutasteride on the inhibition of low-risk, localized prostate cancer progression in men who would otherwise receive no active therapy (expectant management).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dutasteride | Dutasteride 0.5mg |
| DRUG | Matching placebo | Matching placebo |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2010-03-01
- Completion
- 2010-07-01
- First posted
- 2006-08-15
- Last updated
- 2017-01-18
- Results posted
- 2011-06-14
Locations
82 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00363311. Inclusion in this directory is not an endorsement.